ZD1839 (Iressa™) in non-small cell lung cancer
作者： Roy S. Herbst , Merrill S. Kies
DOI: 10.1634/THEONCOLOGIST.7-SUPPL_4-9
关键词: Internal medicine 、 Oncology 、 Epidermal growth factor receptor 、 Toxicity 、 Cisplatin 、 Orally active 、 Kinase 、 Medicine 、 Combination chemotherapy 、 Lung cancer 、 Non small cell
摘要: Despite the advent of cisplatin-based combination chemotherapy for advanced non-small cell lung cancer (NSCLC), prognosis this patient population remains poor. Novel biologically targeted agents currently in development have potential greater efficacy against NSCLC, and possibly less toxicity than is associated with conventional cytotoxic chemotherapy. The epidermal growth factor receptor (EGFR) recognized as a potentially useful target, small molecule, orally active EGFR-tyrosine kinase inhibitor ZD1839 (Iressa) furthest along clinical anti-EGFR agents. This review summarizes available data on use treatment NSCLC.
alphamedpress.org 参考文章(16)
Spaventi S, Pavelic K, Banjac Z, Pavelic J, Evidence for a role of EGF receptor in the progression of human lung carcinoma Anticancer Research. ,vol. 13, pp. 1133- 1137 ,(1993)
V. Rusch, Ethan Dmitrovsky, C. Cordon-Cardo, S. Hoda, M. Zaman, Jonathan M Kurie, J. Mcintosh, J. Baselga, J. Orazem, Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung Cancer Research. ,vol. 53, pp. 2379- 2385 ,(1993)
Mark G. Kris, Howard I. Scher, Vincent A. Miller, Maureen F. Zakowski, Francis M. Sirotnak, Efficacy of Cytotoxic Agents against Human Tumor Xenografts Is Markedly Enhanced By Coadministration of ZD1839 (Iressa), an Inhibitor of EGFR Tyrosine Kinase Clinical Cancer Research. ,vol. 6, pp. 4885- 4892 ,(2000)
Frank V. Fossella, Russell DeVore, Ronald N. Kerr, Jeffrey Crawford, Ronald R. Natale, Frank Dunphy, Leonard Kalman, Vincent Miller, Jin Soo Lee, Melvin Moore, David Gandara, Daniel Karp, Everett Vokes, Mark Kris, Yong Kim, Francis Gamza, Luz Hammershaimb, , Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens Journal of Clinical Oncology. ,vol. 18, pp. 2354- 2362 ,(2000) , 10.1200/JCO.2000.18.12.2354
Karen Kelly, John Crowley, Paul A. Bunn, Cary A. Presant, Patra K. Grevstad, Carol M. Moinpour, Scott D. Ramsey, Antoinette J. Wozniak, Geoffrey R. Weiss, Dennis F. Moore, Valerie K. Israel, Robert B. Livingston, David R. Gandara, Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial Journal of Clinical Oncology. ,vol. 19, pp. 3210- 3218 ,(2001) , 10.1200/JCO.2001.19.13.3210
Ronald B. Natale, Susan L. Zaretsky, ZD1839 (Iressa™): What’s in It for the Patient? Oncologist. ,vol. 7, pp. 25- 30 ,(2002) , 10.1634/THEONCOLOGIST.7-SUPPL_4-25
M.G Kris, R Herbst, D Rischin, P LoRusso, J Baselga, L Hammond, A Feyereislova, J Ochs, S Averbuch, Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 (IressaTM), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR) Lung Cancer. ,vol. 29, pp. 72- ,(2000) , 10.1016/S0169-5002(00)80233-0
M Volm, W Rittgen, P Drings, Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. British Journal of Cancer. ,vol. 77, pp. 663- 669 ,(1998) , 10.1038/BJC.1998.106
Joan H. Schiller, David Harrington, Chandra P. Belani, Corey Langer, Alan Sandler, James Krook, Junming Zhu, David H. Johnson, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. The New England Journal of Medicine. ,vol. 346, pp. 92- 98 ,(2002) , 10.1056/NEJMOA011954
Frances A. Shepherd, Janet Dancey, Rodryg Ramlau, Karin Mattson, Richard Gralla, Mark O’Rourke, Nathan Levitan, Laurent Gressot, Mark Vincent, Ronald Burkes, Susan Coughlin, Yong Kim, Jocelyne Berille, Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy Journal of Clinical Oncology. ,vol. 18, pp. 2095- 2103 ,(2000) , 10.1200/JCO.2000.18.10.2095